Because combination of Bevacizumab with EGFR TK inhibitors showed improved tumor response, we assessed the combined effect of osimertinib plus bevacizumab in these three tumor models of NSCLC (Fig 4 and S8–S10 Figs). The gene discussed is EGFR; the disease is neoplasm.